4 results on '"Buliubasich, Sandra"'
Search Results
2. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort
- Author
-
Shinjo, Samuel K., Bonfá, Eloísa, Wojdyla, Daniel, Borba, Eduardo F., Ramirez, Luis A., Scherbarth, Hugo R., Brenol, João C. Tavares, Chacón-Diaz, Rosa, Neira, Oscar J., Berbotto, Guillermo A., de la Torre, Ignacio Garcia, Acevedo-Vázquez, Eduardo M., Massardo, Loreto, Barile-Fabris, Leonor A., Caeiro, Francisco, Silveira, Luis H., Sato, Emilia I., Buliubasich, Sandra, Alarcón, Graciela S., and Pons-Estel, Bernardo A.
- Published
- 2010
- Full Text
- View/download PDF
3. Antimalarial Treatment May Have a Time-Dependent Effect on Lupus Survival
- Author
-
Shinjo, Samuel Katsuyuki [UNIFESP], Bonfa, Eloisa, Wojdyla, Daniel, Borba, Eduardo F., Ramirez, Luis A., Scherbarth, Hugo R., Tavares Brenol, Joao C., Chacon-Diaz, Rosa, Neira, Oscar J., Berbotto, Guillermo A., Garcia de La Torre, Ignacio, Acevedo-Vazquez, Eduardo M., Massardo, Loreto, Barile-Fabris, Leonor A., Caeiro, Francisco, Silveira, Luis H., Sato, Emilia Inoue [UNIFESP], Buliubasich, Sandra, Alarcon, Graciela S., Pons-Estel, Bernardo A., Grp Latino Amer Estudio Lupus Erit, Hosp Prov Rosario, Universidade de São Paulo (USP), Univ Nacl Rosario, Univ Antioquia, Hosp Univ San Vicente de Paul, Hosp Interzonal Gen Agudos Dr Oscar Alende, Hosp Clin Porto Alegre, Univ Fed Rio Grande do Sul, Hosp Univ Caracas, Hosp Salvador, Univ Chile, Hosp Escuela Eva Peron, Hosp Gen Occidente Secretaria Salud, Hosp Nacl Guillermo Almenara Irigoyen, Pontificia Univ Catolica Chile, Hosp Especialidades Ctr Med Nacl Siglo XXI, Hosp Privado, Inst Nacl Cardiol Ignacio Chavez, Universidade Federal de São Paulo (UNIFESP), Hosp Nacl Clin, and Univ Alabama
- Abstract
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Federico Wilhelm Agricola Foundation Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large, multiethnic, international longitudinal inception cohort.Methods. Socioeconomic and demographic characteristics, clinical manifestations, classification criteria, laboratory findings, and treatment variables were examined in patients with systemic lupus erythematosus (SLE) from the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort. the diagnosis of SLE, according to the American College of Rheumatology criteria, was assessed within 2 years of cohort entry. Cause of death was classified as active disease, infection, cardiovascular complications, thrombosis, malignancy, or other cause. Patients were subdivided by antimalarial use, grouped according to those who had received antimalarial drugs for at least 6 consecutive months (user) and those who had received antimalarial drugs for 2 years. Mortality rates among users by duration of antimalarial treatment (per 1,000 person-months of followup) were 3.85 (95% confidence interval [95% CI] 1.41-8.37), 2.7 (95% CI 1.41-4.76), and 0.54 (95% CI 0.37-0.77), respectively, while for nonusers, the mortality rate was 3.07 (95% CI 2.18-4.20) (P for trend < 0.001). After adjustment for potential confounders in a Cox regression model, antimalarial use was associated with a 38% reduction in the mortality rate (hazard ratio 0.62, 95% CI 0.39-0.99).Conclusion. Antimalarial drugs were shown to have a protective effect, possibly in a time-dependent manner, on SLE survival. These results suggest that the use of antimalarial treatment should be recommended for patients with lupus. Hosp Prov Rosario, Rheumatol Serv, RA-2000 Rosario, Santa Fe, Argentina Univ São Paulo, Fac Med, Hosp Clin, São Paulo, Brazil Univ Nacl Rosario, RA-2000 Rosario, Santa Fe, Argentina Univ Antioquia, Medellin, Colombia Hosp Univ San Vicente de Paul, Medellin, Colombia Hosp Interzonal Gen Agudos Dr Oscar Alende, Mar Del Plata, Buenos Aires, Argentina Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil Hosp Univ Caracas, Caracas, Venezuela Hosp Salvador, Santiago, Chile Univ Chile, Santiago, Chile Hosp Escuela Eva Peron, Rosario, Santa Fe, Argentina Hosp Gen Occidente Secretaria Salud, Guadalajara, Jalisco, Mexico Hosp Nacl Guillermo Almenara Irigoyen, Lima, Peru Pontificia Univ Catolica Chile, Santiago, Chile Hosp Especialidades Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Mexico City, DF, Mexico Hosp Privado, Ctr Med Cordoba, Cordoba, Argentina Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico Universidade Federal de São Paulo, São Paulo, Brazil Hosp Nacl Clin, Cordoba, Argentina Univ Alabama, Birmingham, W Midlands, England Universidade Federal de São Paulo, EPM, São Paulo, Brazil CNPq: 305468/2006-5 CNPq: 3031165/2008-1 Web of Science
- Published
- 2010
4. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children.
- Author
-
Ramírez Gómez LA, Uribe Uribe O, Osio Uribe O, Grisales Romero H, Cardiel MH, Wojdyla D, Pons-Estel BA, Catoggio LJ, Soriano ER, Imamura PM, Manni JA, Grimaudo S, Sarano J, Maldonado-Cocco JA, Arriola MS, Gómez G, García MA, Marcos AI, Marcos JC, Scherbarth HR, Marino PC, Motta EL, Drenkard C, Gamron S, Buliubasich S, Onetti CM, Caeiro F, Alvarellos A, Saurit V, Gentiletti S, Quagliatto N, Gentiletti AA, Machado D, Abdala M, Palatnik S, Berbotto GA, Battagliotti CA, Sato E, Sella EM, Souza AS, Costallat LT, Bertolo MB, Coimbra IB, Borba Neto EF, Bonfá E, Tavares JC, Brenol, Xavier R, Mucenic T, Cavalcanti Fde S, Duarte AL, Marques CD, Da Silva NA, de O e Silva AC, Pacheco TF, Molina-Restrepo JF, Molina-López J, Iglesias-Gamarra A, Iglesias-Rodríguez A, Egea-Bermejo E, Guzmán-Moreno RA, Restrepo-Suárez JF, Guibert-Toledano M, Reyes-Llerena GA, Massardo L, Gareca N, Jacobelli S, Neira OJ, Guzmán LR, Garcia-Kutzbach A, Castellanos C, Cajas E, Pascual-Ramos V, Barile-Fabris LA, Miranda-Limón JM, Amigo MC, Silveira LH, De La Torre IG, Orozco-Barocio G, Estrada-Contreras ML, del Pozo MJ, Aranda Baca LE, Quezada AU, Huerta-Yáñez GF, Acevedo-Vásquez EM, Alfaro-Lozano JL, Cucho-Venegas JM, Segami MI, Chung CP, Alva-Linares M, Abadi I, Chacón-Díaz R, Al Snih Al Snih S, Esteva-Spinetti MH, and Vivas J
- Subjects
- Adolescent, Adult, Age of Onset, Child, Female, Humans, Latin America epidemiology, Male, Lupus Erythematosus, Systemic epidemiology, Lupus Erythematosus, Systemic physiopathology
- Abstract
To evaluate disease characteristics of childhood onset SLE in Latin America and to compare this information with an adult population in the same cohort of GLADEL. A protocol was designed as a multicenter, multinational, inception cohort of lupus patients to evaluate demographic, clinical, laboratory and serological variables, as well as classification criteria, disease activity, organ damage and mortality. Descriptive statistics, chi square, Fisher's exact test, Student's t test and multiple logistic regression were used to compare childhood and adult onset SLE. 230 patients were <18 years and 884 were adult SLE patients. Malar rash, fever, oral ulcers, thrombocytopenia and hemolytic anemia and some neurologic manifestations were more prevalent in children (p<0.05). On the other hand, myalgias, Sjögren's syndrome and cranial nerve involvement were more frequently seen in adults (p<0.05). Afro-Latin-American children had a higher prevalence of fever, thrombocytopenia and hemolytic anemia. White and mestizo children had a higher prevalence of malar rash. Mestizo children had a higher prevalence of cerebrovascular disease and cranial nerve involvement. Children met SLE ACR criteria earlier with higher mean values than adults (p: 0.001). They also had higher disease activity scores (p: 0.01), whereas adults had greater disease damage (p: 0.02). In Latin America, childhood onset SLE seems to be a more severe disease than adults. Some differences can be detected among ethnic groups.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.